Romano G, Michell P, Pacilio C, Giordano A
Kimmel Cancer Institute, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
Stem Cells. 2000;18(1):19-39. doi: 10.1634/stemcells.18-1-19.
Over the last decade, more than 300 phase I and phase II gene-based clinical trials have been conducted worldwide for the treatment of cancer and monogenic disorders. Lately, these trials have been extended to the treatment of AIDS and, to a lesser extent, cardiovascular diseases. There are 27 currently active gene therapy protocols for the treatment of HIV-1 infection in the USA. Preclinical studies are currently in progress to evaluate the possibility of increasing the number of gene therapy clinical trials for cardiopathies, and of beginning new gene therapy programs for neurologic illnesses, autoimmuno diseases, allergies, regeneration of tissues, and to implement procedures of allogeneic tissues or cell transplantation. In addition, gene transfer technology has allowed for the development of innovative vaccine design, known as genetic immunization. This technique has already been applied in the AIDS vaccine programs in the USA. These programs aim to confer protective immunity against HIV-1 transmission to individuals who are at risk of infection. Research programs have also been considered to develop therapeutic vaccines for patients with AIDS and generate either preventive or therapeutic vaccines against malaria, tuberculosis, hepatitis A, B and C viruses, influenza virus, La Crosse virus, and Ebola virus. The potential therapeutic applications of gene transfer technology are enormous. However, the effectiveness of gene therapy programs is still questioned. Furthermore, there is growing concern over the matter of safety of gene delivery and controversy has arisen over the proposal to begin in utero gene therapy clinical trials for the treatment of inherited genetic disorders. From this standpoint, despite the latest significant achievements reported in vector design, it is not possible to predict to what extent gene therapeutic interventions will be effective in patients, and in what time frame.
在过去十年间,全球已开展了300多项基于基因的I期和II期临床试验,用于治疗癌症和单基因疾病。最近,这些试验已扩展到艾滋病治疗,在较小程度上也用于心血管疾病治疗。美国目前有27项正在进行的基因治疗方案用于治疗HIV-1感染。目前正在进行临床前研究,以评估增加心脏病基因治疗临床试验数量以及启动针对神经系统疾病、自身免疫性疾病、过敏、组织再生的新基因治疗项目以及实施同种异体组织或细胞移植程序的可能性。此外,基因转移技术推动了创新疫苗设计的发展,即基因免疫。这项技术已在美国的艾滋病疫苗项目中得到应用。这些项目旨在为有感染风险的个体提供针对HIV-1传播的保护性免疫。还考虑开展研究项目,为艾滋病患者开发治疗性疫苗,并研发针对疟疾、结核病、甲型、乙型和丙型肝炎病毒、流感病毒、拉克罗斯病毒和埃博拉病毒的预防性或治疗性疫苗。基因转移技术的潜在治疗应用极为广泛。然而,基因治疗项目的有效性仍受到质疑。此外,人们对基因递送的安全性问题日益担忧,并且对于开展子宫内基因治疗临床试验以治疗遗传性疾病的提议也引发了争议。从这个角度来看,尽管在载体设计方面有最新的重大成果报道,但无法预测基因治疗干预措施在患者身上的有效程度以及时间范围。